



AIMOVIG™

A NEW INNOVATION IN MIGRAINE

TONY HOOPER—EXECUTIVE VICE PRESIDENT
AMGEN GLOBAL COMMERCIAL OPERATIONS

PAUL HUDSON—CEO, NOVARTIS PHARMACEUTICALS

AMGEN®

SAFE HARBOR STATEMENT

This presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements about estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of May 18, 2018 and expressly disclaims any duty to update information contained in this presentation.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.


MIGRAINE IMPACTS PEOPLE IN THEIR PRIME PRODUCTIVE YEARS AND IS COSTLY TO PATIENTS AND SOCIETY

- **Migraine is among the top-10 causes of disability globally, 4th highest among women**
- **A migraine attack may last up to three days and results in significant loss of productivity**
- **Migraine patients**
 - **Spend ~ 3x more in healthcare costs (\$11K vs. \$4K per year in the U.S.)**
 - **Incur even higher costs if they fail preventive treatments**
- **Migraine also poses a heavy financial toll on employers**

The total economic burden of migraine on the U.S. economy is estimated to be ~ \$23B in medical costs and lost productivity

AIMOVIG™ WILL ADDRESS A TARGETED PATIENT POPULATION

- **Migraine is a highly prevalent, underdiagnosed and undertreated disease**
- **~ 3.5 million U.S. patients currently receive preventive migraine therapy, but compliance is poor due to variable efficacy and poor tolerability**
 - **~ 80% discontinue therapy within one year¹**
 - **Side effects reported as principle reason for discontinuation in up to half of patients**



¹Hepp Z, et al. *Cephalalgia*. 2015;35(6):478-88

AIMOVIG™ IS THE FIRST AND ONLY TREATMENT SPECIFICALLY DESIGNED TO PREVENT MIGRAINE BY TARGETING THE CGRP RECEPTOR

- **Offers a convenient once-monthly, low volume, subcutaneous and self-administered form of dosing**
- **Demonstrated efficacy and safety across a broad range of episodic and chronic migraine patients, including patients with prior preventive medication failure**
 - **Many patients achieved at least a 50% reduction in migraine days**
 - **1 in 5 achieved at least a 75% reduction in migraine days**
- **Long-term safety profile established in over 3,000 patients, out to two years**
 - **In clinical trials, 95% of patients were able to stay on Aimovig™**

CGRP = calcitonin gene-related peptide

Provided May 18, 2018, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AIMOVIG™ NOW APPROVED

- Aimovig™ is indicated for the preventive treatment of migraine in adults
- The recommended dosage of Aimovig™ is 70 mg injected subcutaneously once monthly, some patients may benefit from a dosage of 140 mg once monthly
- The 140 mg dose is administered as two consecutive subcutaneous injections of 70 mg each
- 1 x 70 mg and 2 x 70 mg SureClick® autoinjector available with plans to submit a sBLA for 1 x 140 mg SureClick® autoinjector in near future



Aimovig™ offers monthly subcutaneous administration with a simple autoinjector and no loading-dose requirements

sBLA = supplemental biologics license application

Provided May 18, 2018, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AIMOVIG™ IS PRICED FOR ACCESS

- **Aimovig™ is priced for fast access at a list price of \$575 per month or \$6,900 per year in support of the population of patients who will benefit**
- **Aimovig™ offers payers the ability to provide value to employers**
- **Payers and PBMs are supportive of our price**

Aimovig™ price addresses current issues with both societal and patient affordability, allowing for broad access for the population who will most benefit

PBM = pharmacy benefit manager

Provided May 18, 2018, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

COMMERCIAL AND PATIENT STRATEGY

Commercial Focus

- **Amgen/Novartis specialty focus in first 30 days**
 - Early adopters
 - High prescribers
 - Key influencers
 - Neurologists and PCPs
- **Driving patient requests via robust digital outreach**

Patient and Access Programs

- **Aimovig Ally™ support services**
 - Patient support line
 - Navigation of insurance coverage
 - Access resources
 - Free trial program
- **Aimovig™ copay program for commercial patients**

Amgen and Novartis are committed to lead the fight against migraine

PCP = primary care physician

Provided May 18, 2018, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AIMOVIG™: AN INNOVATIVE NEW OPTION FOR MIGRAINE PATIENTS



Unique Approach	Sustained and Consistent Efficacy	Robust Data Package	Safety and Tolerability Established Across Clinical Studies
<ul style="list-style-type: none"> • First and only mAb to target and block the CGRP receptor • Only fully human anti-CGRP mAb 	<ul style="list-style-type: none"> • Efficacy across a range of patients • Aimovig™ reduced monthly migraine days in patients with episodic and chronic migraine, including patients with prior preventative medication failure, and many patients achieved at $\geq 50\%$ reduction 	<ul style="list-style-type: none"> • Over 3,000 patients; five year ongoing extension • Efficacy in prior treatment failures, medication overuse patients 	<ul style="list-style-type: none"> • Most common adverse events in clinical studies were injection site reactions and constipation • In clinical studies, up to 95% of patients were able to start and stay on therapy

Aimovig™ will be available to patients within one week



AIMOVIG™

A NEW INNOVATION IN MIGRAINE

TONY HOOPER—EXECUTIVE VICE PRESIDENT
AMGEN GLOBAL COMMERCIAL OPERATIONS

PAUL HUDSON—CEO, NOVARTIS PHARMACEUTICALS

AMGEN®